Dalton Trans., 2023, 52,14110-14122
DOI: 10.1039/D3DT02030D, Paper
DOI: 10.1039/D3DT02030D, Paper
Open Access
This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.Darren Fergal Beirne, Barbara Farkaš, Chiara Donati, Valentina Gandin, Isabel Rozas, Trinidad Velasco-Torrijos, Diego Montagner
A novel strategy for the development of Pt(IV) cisplatin-based prodrugs with tyrosine kinase inhibitors (TKi's) containing a detailed theoretical approach, synthesis, chemical characterization and preliminary results as anticancer agents and TKi's
The content of this RSS Feed (c) The Royal Society of Chemistry
A novel strategy for the development of Pt(IV) cisplatin-based prodrugs with tyrosine kinase inhibitors (TKi's) containing a detailed theoretical approach, synthesis, chemical characterization and preliminary results as anticancer agents and TKi's
The content of this RSS Feed (c) The Royal Society of Chemistry